The concern of generic challenges has long loomed above copyright’s famous drug, PDE5 Inhibitor, triggering questions about the prospects of related pharmaceutical portfolios. While early times saw impressive profits, the exclusivity end has allowed the path for cheaper substitutes, possibly diminishing earnings and presenting a significant hazar